Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700149 · ClinicalTrials.gov registry record
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
A clinical trial of Nodal Marginal Zone Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG).
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT05700149: Recruiting study of Nodal Marginal Zone Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG).
NCT05700149 is a study of Nodal Marginal Zone Lymphoma that is actively recruiting participants, run by International Extranodal Lymphoma Study Group (IELSG). The registered enrollment target is 300 participants. The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05700149, a study of Nodal Marginal Zone Lymphoma, is actively recruiting participants, sponsored by International Extranodal Lymphoma Study Group (IELSG).
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Conditions Studied
Study Locations (20)
MI
- IRCCS Ospedale San Raffaele - Milan
- IEO Istituto Europeo di Oncologia - Milan
- ASST Grande Ospedale Metropolitano Niguarda - Milan
Other
- Hematology Center after Prof. Yeolyan - Yerevan
- University Hospital Centre Zagreb - Zagreb
Florida
- University of Miami - Miami
New York
- Weill Cornell Medical - New York
AL
- AO SS Antonio e Biagio e C. Arrigo - Alessandria
BA
- Istituto Tumori "Giovanni Paolo II" I.R.C.C.S. - Bari
BG
- ASST Papa Giovanni XXIII - Bergamo
BS
- ASST degli Spedali Civili di Brescia - Brescia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2026-12-31 |
What NCT05700149 shows while recruiting
NCT05700149 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Nodal Marginal Zone Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT05700149 names 20 study sites across 17 states, led by MI, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT05700149 about?
NCT05700149 is a clinical study titled "Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma". International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
What is the current status of trial NCT05700149?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-04-11. Estimated completion is 2026-12-31.
What conditions does trial NCT05700149 study?
This clinical trial studies the following conditions: Nodal Marginal Zone Lymphoma.
Who is sponsoring clinical trial NCT05700149?
This trial is sponsored by International Extranodal Lymphoma Study Group (IELSG), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05700149 being conducted?
This trial has 20 study locations across Florida, New York, AL, BA, BG. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nodal Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI